NCT06795178View on ClinicalTrials.gov

Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced Prostate Cancer

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 1, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

February 2, 2028

Conditions
Prostate Cancer
Interventions
DRUG

FP-014

11.25 mg in a prefilled, ready-to-use, long-acting formulation

Sponsors
All Listed Sponsors
collaborator

QPS Holdings LLC

INDUSTRY

lead

Foresee Pharmaceuticals Co., Ltd.

INDUSTRY